Association for Women in Science’s Post

🌟 Super early bird discount alert! 🌟 Don't miss out on the opportunity to join us at the 7th Annual MarketsandMarkets Real-World Evidence and Life Sciences Analytics Conference, happening on October 17th - 18th, 2024 in Boston! Our conference is set to bring together a diverse range of experts, leaders, and stakeholders, all converging to share insights and perspectives on crucial industry points. With a focus on best practices, attendees will engage in discussions aimed at enhancing decision-making processes. Real-World Evidence (RWE) solutions stand at the forefront of innovation, offering invaluable tools for both industrial and academic researchers. Through digitally connected platforms, RWE enables continuous patient monitoring and facilitates the organization and evaluation of clinical data for regulatory submissions. However, as the field of RWE research continues to evolve, it becomes increasingly evident that certain gaps remain unexplored. That's why our conference aims to provide guidance and foster consensus on essential annotations, ultimately driving the effective utilization of real-world data. Take advantage of this chance to stay ahead in this dynamic field by grabbing your super early bird discount now! Come to Boston for two days of unmatched learning, networking, and collaboration. Don't wait - register today and enjoy savings! DM or reach out to me at nikhil.jain@marketsandmarkets.com to know more! Note: Discounts are valid only until 25th May for first 30 registrants. To learn more about the conference: https://lnkd.in/d4kqnDf4 #RWE #LifeSciences #Analytics #Boston #EarlyBirdSpecial #realworlddata #realworldevidence #healthcare #advancedmedicine #lifesciencesanalytics #lifesciences #conference2024 #healthcare #pharma #marketsandmarkets #RWDL2024 #bostonconference2024 #rwdlboston2024

Recently, my colleague Mads Delcin Faurby and I had the incredible opportunity to travel from our base in Plainsboro to the Novo Nordisk BioInnovation Hub in Boston to give a market perspective on the unmet medical needs in obesity and T2D, the competitive environment and value. We had a great dialogue around the innovation to come for patients living with serious chronic disease with our colleagues, who are working with early, innovative and cutting-edge assets to help drive change for patients living with serious chronic diseases. The idea was to foster collaboration between the early and late parts of the value chain, and to provide a market perspective on the unmet needs, ultimately helping our colleagues to make bold decisions when it comes to developing future innovations for patients obesity and T2D. It was an amazing crowd, and we heard some pretty wild ideas for future treatment modalities! We saw a few familiar faces, met new people, made connections across the organization, and came up with new and creative ideas for collaboration. And to top it off, it all happened in beautiful surroundings! Taking time out of a busy schedule to connect with colleagues and share cross-functional knowledge is tough. But it’s extremely important to take that time to foster the needed collaboration across the value chain, to ensure end-to-end thinking, while keeping patient needs in mind. This was one way to do it. What are you doing to foster collaboration with colleagues you usually don’t engage with? We should encourage colleagues to collaborate on things like this; to share ideas and educate and inspire each other, all the while increasing their knowledge of the organization and the drug development value chain and fostering an enterprise mindset. Thank you, Trine Pagh Ludvigsen Cecilie Heerdegen Jepsen. MD, PhD Sebastian Beck Jørgensen and Uli Stilz for inviting us – it was a true pleasure! #NovoNordisk #Innovation #Collaboration #Healthcare #DrugDevelopment #BioInnovationHub

Recently, at the Novo Nordisk Foundation Global Science Summit 2024 in Denmark, three of the world's most highly regarded foundations: Novo Nordisk Foundation, the Bill & Melinda Gates Foundation, and the Wellcome Trust, announced a three-year partnership aimed at addressing the health impacts of climate change. The initial funding of $300 million will support solutions accessible to Low- and Middle-Income Countries, focusing on climate resilience, disease surveillance, and understanding health interactions. “By pooling the vast experience and unique expertise of each organization - across research, technology, innovation, and enterprise - we can make advances that wouldn’t otherwise be possible,” said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation. The initiative emphasizes direct support for researchers to foster local innovation. The CEOs of the three foundations express optimism in scientific solutions and call for expanded collaboration across sectors to advance global health research. They envision philanthropy as a catalyst for broader partnerships in addressing global health disparities. This partnership aligns with gMendel®'s innovative diagnostic solution of genetic disorders that contributes to addressing global health challenges. The societal burden of the rare diseases exceeds €2 trillion worldwide, and the lifetime costs of disease management exceeds $2.5 million per patient, but early accurate diagnosis could save $500,000 per patient. This demonstrates a clear unmet clinical need for better, faster, and affordable screening and diagnosis of rare diseases that could significantly improve patient outcomes, reduce healthcare costs, and enhance the efficiency of the entire diagnostic process. #genetics #genomics #screening #diagnostics #rarediseases #geneticdisorders #healthcare #innovation #healthtech #AI #artificialintelligence #machinelearning #companiondiagnostics #precisionmedicine #VC #venturecapital https://lnkd.in/eFTrr4qM

Recently, my colleague Azadeh Houshmand-Øregaard and I had the incredible opportunity to travel from our base in Plainsboro to the Novo Nordisk BioInnovation Hub in Boston to give a market perspective on the unmet medical needs in obesity and T2D, the competitive environment and value. We had a great dialogue around the innovation to come for patients living with serious chronic disease with our innovative colleagues, who are working with very early, innovative and cutting-edge assets to help drive change for patients living with serious chronic diseases. The idea was to foster collaboration between the very early part of the value chain and the end of the value chain, to provide a market perspective on the unmet needs hopefully helping them to make bold decisions when it comes to develop to future innovations for patients with type II diabetes and obesity. It is an amazing crowd, and it turns out there are some pretty wild ideas for future treatment modalities cooking out there! We saw a few familiar faces, met new people, made connections across the organization, and came up with new and creative ideas for collaboration. And to top it all off, it all happened in beautiful surroundings! Taking time out of a busy schedule to connect with colleagues and share cross-functional knowledge is tough. But I think it’s extremely important to take that time to foster the needed collaboration across the value chain to ensure end-to-end thinking across the drug development value chain keeping the patient needs in mind. This was one way to do it. What are you doing to foster collaboration with colleagues you usually don’t engage with?  One of the ways to do that is by encouraging colleagues to collaborate on things like this; to share ideas, educate each other, and get inspired to increase their knowledge of the organization, of the drug development value chain, and encourage an enterprise mindset. Thank you, Trine, Cecilie, Sebastian and Uli for inviting us – it was a true pleasure! #NovoNordisk #Innovation #Collaboration #Healthcare #DrugDevelopment #BioInnovationHub

FREE conference today and tomorrow!!! If you are Sponsor in San Diego and have some free time today, come check out OCT Southern California at the Hyatt Regency La Jolla. There is an interesting session at 2PST: PANEL: Considerations for a Patient Centric Trial Design to Increase Trial Success - Exploring patient collaboration and the benefits it can bring to the sponsor and the patient. - Importance of good communication to the patients and how this can streamline trial timelines - Exploring how patients could, and should, be influencing decisions and the R&D process before study start-up. - How to optimize collaboration with patient advocacy organizations Patient perspective ‘Pain Points’ throughout various trials Speakers: Jessica Hatheway Jessica Hatheway MBA, Vice President, Clinical Operations, Daré Bioscience Constance Crowley Constance Crowley Executive Director/Senior Clinical Scientist, Arcturus Therapeutics Dr. Paul Grint Paul Grint Executive Chairman, Codagenix Nick Tresnowski Nick Tresnowski Director of Operations, LEAPCURE

Our newest on-demand panel discussion delves into the intersection of real-world evidence (RWE), the patient voice, and their collective impact on clinical trial methodologies including: 📊 Supplementing traditional clinical trial data with real-world insights. 📈 Fostering a more comprehensive understanding of treatment outcomes, patient populations and safety profiles from leveraging RWE. 📣 Shaping the trajectory of clinical trials through the pivotal role of the patient voice. 💡 Illuminating the tangible benefits of adopting patient-centered approaches. Learn more: https://lnkd.in/eRHs5fD9 Yosef Khan, Northwell Health

C Space Health (Samantha Mason, Jeff Morrill and Kristin Masoud) enjoyed connecting with clients, colleagues and friends at this year's Pharma Market Research Conference PMRC last week! Of particular note was our at-capacity round table where we discussed successes and challenges of incorporating social determinants of health (SDOH) into insights work.   Just a few key takeaways: Have the privacy team on speed dial as populations of interest get smaller and smaller; get creative with sourcing to find those harder-to-reach individuals; cheaper and faster is not always possible with these populations when it needs to be inclusive — and that's OK!   Thanks to Chris O'Konis of Sarepta Therapeutics for sharing your experiences with the group, and to everyone who attended from Organon Merck ViiV Healthcare Purdue Pharma L.P. Dyne Therapeutics and more. #Escalent #pharmaindustry #healthcare #SDOH #insights #marketresearch #inclusion Visit ➡ https://lnkd.in/e62qeEFA to learn more about C Space Health! Hall & Partners Escalent

Such an energizing two days hearing about pharma market research innovations, and sharing our own! My biggest takeaway was regarding the deep integration of market research with analytics--and how seamlessly blending the two is a new definition of agile. If you’d like to learn how C Space Health, Escalent, and Hall & Partners help our clients win in the market by connecting more closely with their customers (patients, healthcare providers, and caregivers), please get in touch! #learninganddevelopment #healthcare #patientexperience #patientinsights

Behavioral Science for Better Health! Don’t miss this event event to learn how to improve the efficacy of your communication in the healthcare sector. A major topic with fantastic speakers from Novartis and BVA Nudge Consulting #behavioralscience #healthcare #healthliteracy #nudge #communication

🚀I'm thrilled to announce that I'll be speaking at the upcoming DIA Global Meeting, taking place in San Diego, US, between 16-20 June, on a topic that's close to my heart: Digital Biomarkers as Clinical Endpoints - The Road to Regulatory Acceptability. 💡In an era where technology and healthcare are increasingly intertwined, digital biomarkers offer groundbreaking potential to revolutionize clinical trials and patient care. This session will explore how we can harness these innovative tools to meet regulatory standards and improve health outcomes worldwide. 🔍In my speech, I'll be diving deep into the current landscape of digital biomarkers, with the focus on Europe, and exploring the path towards wider regulatory acceptance. I'll be sharing real-world examples and @Bayer’s perspective to help us navigate this exciting new frontier in clinical research. 🙏I'm especially grateful to Susan Awad and Lina AlJuburi for inviting me to share the industry insights on this critical topic. Digital biomarkers have the potential to revolutionize clinical trials, offering a more objective and efficient way to measure treatment effects. However, their regulatory acceptance is still evolving. 🌐 If you're interested in the future of clinical trials and the potential of digital biomarkers, then be sure to join the conference! I look forward to a stimulating discussion and the opportunity to connect with fellow leaders in the healthcare industry. hashtag #digitalhealth hashtag #clinicaltrials hashtag #regulatoryaffairs hashtag #globalhealthcare hashtag #digitalbiomarkers hashtag #DIA2024 https://ow.ly/XxFR50QwsWt Steve Berman – BIO, Deputy Vice President, Science and Regulatory Affairs Strategy Gul Erdemli – Novartis, Global Program Regulatory director Anindita (Annie) Saha – FDA Associate Director for Strategic Initiatives, Digital Health Center of Excellence Marwan Fathallah, President and Chief Executive Officer, DIA Global Ania Mitan, DIA Susan Benedetti, MSOL, DES, Senior Project Manager, Global Annual Meeting Maureen Lamplugh, Retired, Former Annual Meeting Program Manager, DIA Christian Rommel, Bayer AG Stefan Oelrich, Bayer AG Elena Popa, Bayer AG Antoine Manson, Bayer AG